ETFs & MarketsPremiumPfizer Raises 2026 Outlook: What it Means for Pharma ETFs
Pfizer has updated its 2026 financial outlook, projecting revenues between $62 billion and $64 billion and adjusted earnings per share of $2.95-$3.05. This upward revision signals potential shifts within the pharmaceutical sector, impacting related exchange-traded funds.
Published 2 hours ago
Read more →